FDA grants pediatric exclusivity for PLAVIX: sanofi-aventis, Bristol-Myers Squibb
Exclusivity for PLAVIX in the US is now scheduled to expire on 17 May 2012. According to sanofi-aventis and Bristol-Myers Squibb, PLAVIX has been shown to decrease the
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.